(VIANEWS) – The NYSE opens in less than one hour and Catalent‘s pre-market value is already 7.39% down.

The last session, NYSE finished with Catalent (CTLT) sliding 3.78% to $76.07. NYSE fell 2.26% to $13,796.99, after four successive sessions in a row of losses, on what was an all-around negative trend trading session.

About Catalent

Catalent, Inc., along with its affiliates, creates and produces solutions for pharmaceuticals, protein-based biologics, cell, gene therapy, and other consumer products. The company operates in four areas: Biologics and Softgel and Oral Technologies; Oral and Specialty Delivery; Clinical Supply Services and Biologics. Softgel and Oral Technologies provides manufacturing, formulation and development services for soft capsules that can be used in various customer products such as prescription drugs and over-the-counter medicines, nutritional supplements, unit-dose cosmetics and animal health medicinal preparations. The Biologics Segment provides biologic cell-line, develops and produces cell therapy, viral based gene therapies, formulation, development, manufacturing parenteral dosage forms including vials prefilled with syringes or vials and cartridges as well as analytical and testing services. Oral and Specialty Delivery offers manufacturing, formulation and development across many technologies, as well as integrated downstream clinical development and supply solutions. The segment offers oral delivery services that include pre-clinical screening and formulation as well as analytical development. Clinical Supply Services offers manufacturing, storage, distribution and inventory management services for biologics and drugs clinical trials. The company also provides FastChain clinical supply services. It serves companies in the pharmaceutical and biotechnology industries as well as those in healthcare markets such as cosmetics and animal health. Catalent, Inc., was founded in 2007. It is located in Somerset, New Jersey.

Earnings Per Share

As for profitability, Catalent has a trailing twelve months EPS of 1.8.

PE Ratio

Catalent has a trailing 12 months price to earnings ratio of 42.15. Meaning,
the purchaser of the share is investing $42.15 for every dollar of annual earnings.

Return on Equity (TTM)

Catalent’s ROE is 11.79.


Today’s last reported volume for Catalent is 2406883, 102.31% above its average volume of 1189676.

Catalent’s last close was $76.07, 46.46% under its 52-week high of $142.09.

Catalent’s Revenue

Year-on-year quarterly revenue growth grew by 20.9%, now sitting on 4.7B for the twelve trailing months.


Catalent’s last day, last week, and last month’s current intraday variation average was 3.93%, 4.60%, and 2.55%, respectively.

Catalent’s highest amplitude of average volatility was 4.68% (day), 4.87% (last week), and 3.40% (last month), respectively.

More news about Catalent (CTLT).


Please enter your comment!
Please enter your name here